Genova Biotechniques Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
- Paid Up Capital ₹ 5.11 Cr
- Company Age 23 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.86 M
- Revenue Growth 13.10%
- Profit Growth 49.99%
- Ebitda 93.92%
- Net Worth 27.37%
- Total Assets 97.13%
About Genova Biotechniques
Genova Biotechniques Private Limited (GBPL) is a leading Private Limited Indian Non-Government Company incorporated in India on 05 July 2001 and has a history of 23 years and six months. Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 5.11 Cr.
The company currently has active open charges totaling ₹1.86 M.
Mitra Puchhalapalli, Trimurthulu Guna, and Nurjahan Shaik serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U01110TG2001PTC036979
- Company No.
036979
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
05 Jul 2001
- Date of AGM
28 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Genova Biotechniques?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Mitra Puchhalapalli  | Managing Director | 05-Jul-2001 | Current |
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Trimurthulu Guna | Whole-Time Director | 02-Nov-2009 | Current |
| Nurjahan Shaik | Additional Director | 06-Jan-2023 | Current |
Financial Performance of Genova Biotechniques.
Genova Biotechniques Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 13.1% increase. The company also saw a substantial improvement in profitability, with a 49.99% increase in profit. The company's net worth Soared by an impressive increase of 27.37%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Genova Biotechniques?
In 2021, Genova Biotechniques had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Nuevo Therapeutics Private LimitedMitra Puchhalapalli is a mutual person
Charges (Loans)
₹0.19 Cr
₹0
Charges Breakdown by Lending Institutions
- Hdfc Bank Limited : 0.19 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 25 Mar 2021 | Hdfc Bank Limited | ₹1.86 M | Open |
How Many Employees Work at Genova Biotechniques?
Unlock and access historical data on people associated with Genova Biotechniques, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Genova Biotechniques, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Genova Biotechniques's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
